Bayer AG shares climbed sharply in European trading, driven by growing market speculation that the German chemical giant may spin off its glyphosate business.
The rally marks a continuation of the positive sentiment that has enveloped the stock following a recent favorable ruling by the US Supreme Court in the company’s long-running legal battles over cancer risks linked to its Roundup herbicide.
The market move reflects investor appetite for a structural simplification of Bayer’s portfolio.
By potentially separating the glyphosate unit, the company could isolate remaining litigation risks and allow the core crop science and pharmaceutical divisions to be valued more transparently.
This strategic pivot is being viewed as a significant de-risking event for shareholders who have long been exposed to the uncertainty of the Roundup lawsuits.
The share price surge pushed Bayer to the top of the DAX index, underscoring the magnitude of the repricing.